<DOC>
	<DOCNO>NCT00533091</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability multiple IV dose MEDI-545 adult patient myositis .</brief_summary>
	<brief_title>A Study Evaluate Safety Multi-Dose MEDI-545 Adult Patients With Dermatomyositis Polymyositis</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability multiple intravenous ( IV ) dose MEDI-545 adult patient dermatomyositis ( DM ) polymyositis ( PM ) .</detailed_description>
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female adult least 18 year age time randomization ; Written inform consent obtain patient patient 's legal representative prior receipt study medication begin study procedure ; Probable definite PM DM accord Bohan Peter criterion ( Bohan , 1975 ) ; For patient PM , documentation muscle biopsy result consistent diagnosis PM ; All patient include DM must meet least two follow criterion : Strength MMT great ≥ 80/150 ≤ 125/150 use MMT8 muscle group test ; Patient Global Activity Assessment visual analog scale ( VAS ) ≥ 2.0 cm 10 cm scale , include part CLINHAQ ; Physician Global Activity Assessment VAS ≥ 2.0 cm 10 cm scale , include part MDAAT ; CLINHAQ disability index ≥ 0.25 ; Global extramuscular activity assessment ≥ 1.0 cm 10cm VAS scale ( measure physician 's composite evaluation base assessment activity score constitutional , cutaneous , skeletal , gastrointestinal , pulmonary cardiovascular scale MDAAT ; Subjects PM must elevation serum CK aldolase minimum level 1.3 x upper limit normal ( ULN ) serum CK aldolase least 2fold high patient 's low value since diagnosis ; Subjects DM must either elevate CK aldolase ( per inclusion criterion # 6 ) laboratory evidence active myositis . This could include either abnormal signal skeletal muscle MRI suggestive inflammation electromyogram demonstrate muscle membrane irritability ( e.g. , fibrillation potential , positive sharp wave , complex repetitive discharge ) short duration , small amplitude , polyphasic motor unit action potential ; For patient randomize Dose Cohorts 1.2 , 3A 4 : median fold overexpression top 25 type I IFN inducible gene fourfold great whole blood time screening ; For patient randomize dose cohort 3B : low negative expression type I IFNinducible gene ; Sexually active woman , unless surgically sterile ( include tubal ligation ) least 2 year postmenopausal , must use effective method avoid pregnancy ( include oral , injectable , transdermal , implanted contraceptive , intrauterine device , diaphragm spermicide , cervical cap , abstinence , sterile sexual partner ) addition use condom ( male female condom spermicide ) screen end study . Cessation birth control point discuss responsible physician . Sexually active male , unless surgically sterile , must likewise practice two effective method birth control ( condom spermicide abstinence ) must use precaution Study Day 0 end study ; Ability complete study period , include followup period , 350 day ; Willing forego form experimental treatment study . Receipt MEDI545 previous clinical study prior randomization trial ; History allergy reaction component study drug formulation ; Inclusion body myositis , cancerassociated myositis , myositis associate another connective tissue disease , environmentallyassociated myositis , drugrelated myopathy ; A history family history noninflammatory myopathy , scapular winging , atrophy , hypertrophy calf muscle ; Receiving prednisone &gt; 35 mg/day ( equivalent dose another corticosteroid ) within 14 day Study Day 0 ; Receiving follow dosage medication within 28 day Study Day 0 : hydroxychloroquine &gt; 600 mg/day , mycophenolate mofetil &gt; 3 g/day , methotrexate &gt; 25 mg/week , azathioprine &gt; 3 mg/kg/day , dose cyclophosphamide , cyclosporine , thalidomide ; Have receive fluctuating dos antimalarial , mycophenolate mofetil , methotrexate , leflunomide , azathioprine within 28 day Study Day 0 fluctuating dos corticosteroid within 14 day Study Day 0 ; Have receive leflunomide &gt; 20 mg/day 6 month prior Study Day 0 ; Treatment investigational drug therapy within 28 day Study Day 0 biologic therapy ( eg , rituximab ) within 30 day 5 halflives biologic agent , whichever longer , Study Day 0 ; In investigator 's opinion , evidence clinically significant active infection , include ongoing , chronic infection , within 28 day Study Day 0 ; A history severe viral infection judge investigator , include severe infection either CMV herpes family disseminate herpes , herpes encephalitis , ophthalmic herpes ; Herpes zoster ≤ 3 month prior Study Day 0 ; Evidence infection hepatitis B C virus HIV1 HIV2 , active infection hepatitis A , determined result test screening ; Vaccination live attenuate virus within 28 day Study Day 0 ; Pregnancy ( sexually active woman , unless surgically sterile least 2 year postmenopausal , must negative serum pregnancy test screen negative urine pregnancy test prior study drug administration Study Day 0 ) ; Breastfeeding lactate woman ; History alcohol drug abuse &lt; 1 year prior Study Day 0 ; History cancer , except basal cell carcinoma carcinoma situ cervix treat apparent success curative therapy 1 year prior Study Day 0 ; History active tuberculous infection ; History latent tuberculous infection newly positive TB skin test ( reaction define ≥ 10 mm diameter systemic immunosuppressive medication ≥ 5 mm systemic immunosuppressive medication ) without completion appropriate course treatment ongoing prophylactic therapy ; A history coagulation disorder opinion investigator would contraindicate skin muscle biopsy ; Elective surgery plan time screen Study Day 196 ; At screen blood test ( must within 28days Study Day 0 ) following : Serum creatinine &gt; 4.0 mg/dL , Neutrophils &lt; 1,500/mm3 , Platelet count &lt; 50,000/mm3 ; History disease , evidence current disease ( DM PM ) , find upon physical examination , laboratory abnormality , , opinion investigator medical monitor , may compromise safety patient study confound analysis study ; Any employee research site involve conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>